Skip to main content
. 2022 Dec 17;2(2):100562. doi: 10.1016/j.jscai.2022.100562

Table 2.

Procedural characteristics.

Global FlexNav DS cohort (n = 193) CAV group (n = 362)
Anesthesia: conscious sedation 59.1 (114/193) 32.0 (116/362)
Transfemoral access 100.0 (193/193) 95.0 (343/361)
Total fluoroscopy time, min 21.21 ± 8.18 (191) 19.51 ± 63.91 (359)
Pre-BAV performed 94.8 (183/193) 55.4 (200/361)
Final deployed stent depth, mm 4.21 ± 2.75 (176) 4.48 ± 2.34 (266)
Postimplant balloon valvuloplasty 29.5 (57/193) 20.4 (74/362)
Resheathing attempted 43.0 (83/193) NA
Implanted valve sizea, mm
 20.0 NA 1.9 (7/361)
 23.0 2.6 (5/191) 26.9 (97/361)
 25.0 28.8 (55/191) NA
 26.0 NA 41.6 (150/361)
 27.0 32.5 (62/191) NA
 29.0 36.1 (69/191) 24.1 (87/361)
 31.0 NA 1.9 (7/361)
 34.0 NA 3.3 (12/361)
Length of hospital stay, d 3.0 ± 2.3 (193) 2.9 ± 2.2 (362)
Procedural successb 96.9 (187/193) 98.3 (356/362)
Procedural mortalityc 0.0 (0/193) 0.0 (0/362)
Conversion to SAVR 0.0 (0/193) 0.3 (1/362)
Need for a second TAVR valve 3.1 (6/193) 1.4 (5/362)
No valve implanted 0.0 (0/193) 0.0 (0/362)
Successful vascular access 100.0 (193/193) 100.0 (362/362)

BAV, balloon aortic valvuloplasty; CAV, commercially available valve; TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement.

Continuous parameters: values are represented as mean ± SD (n). Categorical parameters: rate per subject (%) is calculated n/N, where n is the number of subjects with an event and N is the total number of subjects at risk. NA refers to data not available.

a

Device size based on the final valve implanted. Two subjects who required a second valve were implanted with a non–Portico valve and not included in this summary.

b

Procedural success is defined as the absence of procedural mortality and correct positioning of a single transcatheter prosthetic heart valve in the proper anatomical location.

c

Procedural mortality is defined as deaths that occurred during the index procedure.